The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1245 Weight Loss articles
The World Health Organization (WHO) has issued new guidelines advocating for the use of GLP-1 drugs in the treatment of obesity. These guidelines suggest that GLP-1 therapies can be used long-term by adults, excluding pregnant women, when combined with intensive behavioral therapy.
With the impending expiration of the Ozempic and Wegovy patents, Indian pharmaceutical giants are gearing up for a significant opportunity in the generics market. Surging obesity rates across India are fueling the demand for affordable weight-loss solutions.
Australia's Therapeutic Goods Administration (TGA) has issued a safety alert concerning Ozempic-style drugs and a potential connection to suicidal thoughts and behaviors. While a direct causal link hasn't been established, the TGA advises patients to immediately inform their healthcare provider if they experience any changes in mood or behavior.
The rise in popularity of weight loss medications such as Ozempic and Mounjaro is significantly impacting both the food industry and the stock market. Eli Lilly, a pharmaceutical company, experienced a surge in valuation after reporting substantial sales increases. These drugs are changing eating patterns and redefining obesity treatment.
Blockbuster weight-loss shots are evolving, with new treatments in development that aim to improve upon current injections. Drugmakers are developing a new wave of GLP-1 treatments, with several promising candidates in the pipeline. These experimental treatments aim to address some of the biggest gripes about today's injections.
Berberine, a compound found in several plants, has gained attention for its potential health benefits, including weight loss and blood sugar regulation. Some compare it to Ozempic, but experts caution about its effectiveness and safety compared to prescription medications.
New weight loss drugs, potentially available in oral form, are under development by Eli Lilly and Novo Nordisk. These medications aim to manage type-2 diabetes and facilitate weight loss, potentially offering a more accessible and convenient alternative to current injectables.
A new Optum Rx report identifies three drugs targeting chronic conditions that are under review by the FDA. The medications address significant cost drivers for payers, including weight management and chronic inflammatory conditions.
A prominent home services company in the UAE has begun delivering weight-loss medications, indicating the sustained popularity of GLP-1 drugs. This move raises discussions about accessibility and safety when obtaining prescription drugs online.
